Hyphens Pharma International Limited (SGX:1J5)

Market Cap	105.02M
Revenue (ttm)	185.32M
Net Income (ttm)	6.46M
Shares Out	308.87M
EPS (ttm)	0.02
PE Ratio	16.62
Forward PE	9.42
Dividend	0.02 (4.35%)
Ex-Dividend Date	May 7, 2025

Volume	74,100
Average Volume	159,115
Open	0.3400
Previous Close	0.3400
Day's Range	0.3400 - 0.3450
52-Week Range	0.2600 - 0.3950
Beta	0.09
RSI	44.08
Earnings Date	Feb 26, 2026

About SGXC:1J5

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Specialty pharma principals; Proprietary brands; and Medical hypermart and digital segments. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products through...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 474
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 1J5

Financial Performance

In 2024, SGXC:1J5's revenue was 195.42 million, an increase of 14.55% compared to the previous year's 170.60 million. Earnings were 10.19 million, an increase of 18.98%.